Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Return on Sales (2016 - 2025)

Altimmune (ALT) has disclosed Return on Sales for 16 consecutive years, with 3802.8% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales rose 76620.0% to 3802.8% in Q3 2025 year-over-year; TTM through Sep 2025 was 4201.65%, a 221050.0% decrease, with the full-year FY2024 number at 4755.35%, down 454773.0% from a year prior.
  • Return on Sales was 3802.8% for Q3 2025 at Altimmune, up from 4429.2% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 1.64% in Q4 2021 to a low of 11783.0% in Q3 2022.
  • A 5-year average of 2731.72% and a median of 2516.5% in 2022 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: crashed -1157091bps in 2022, then skyrocketed 1172590bps in 2023.
  • Altimmune's Return on Sales stood at 1.64% in 2021, then plummeted by -50613bps to 833.08% in 2022, then fell by -3bps to 855.7% in 2023, then tumbled by -445bps to 4659.6% in 2024, then grew by 18bps to 3802.8% in 2025.
  • Per Business Quant, the three most recent readings for ALT's Return on Sales are 3802.8% (Q3 2025), 4429.2% (Q2 2025), and 3915.0% (Q1 2025).